What to Know About This Fund's $74.8 Million Indivior Sale

Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.
Open original source
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.
Open original source